EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab

Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the United States and worldwide with an overall poor prognosis, in part due to limited activity of existing therapy. Primary therapy is largely dictated by the anatomical origin of the cancer and whether distant dise...

Descripción completa

Detalles Bibliográficos
Autores principales: Kono, Scott A., Haigentz, Missak, Yom, Sue S., Saba, Nabil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465896/
https://www.ncbi.nlm.nih.gov/pubmed/23056941
http://dx.doi.org/10.1155/2012/901320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465896/
https://www.ncbi.nlm.nih.gov/pubmed/23056941
http://dx.doi.org/10.1155/2012/901320

Ejemplares similares